ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ALGS vs ELUT // RETURN ON INVESTED CAPITAL (ROIC)

Aligos Therapeutics Inc. (NASDAQ) VS. Elutia Inc. (Class A) (NASDAQ) • 15-METRIC TALLY: ALGS 0 — ELUT 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ALGS VS. ELUT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ALGS ELUT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 53.70% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% 68.00% -128.00 ELUT /net-margins <GO>
Revenue Growth (YoY) -39.50% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 4/9 -2.00 ELUT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.0 48.8 -1.80 ELUT /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $31.4M $36.0M -$4.6M ELUT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ALGS REV ELUT REV ALGS GROSS % ELUT GROSS % ALGS FCF ELUT FCF
FY 2025 $2.2M $12.3M — 53.7% -$82.5M -$46.7M
FY 2024 $3.6M $14.5M — 46.4% -$80.9M -$23.3M
FY 2023 $6.2M $0 — — -$79.0M -$21.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ALGS // BETA —
ELUT // BETA —